Skip to content

Tesamorelin: Dosage & Administration

Part of the Tesamorelin Complete Guide

Partner

Tesamorelin (10mg)

BioLongevity Labs15% Off
Shop Tesamorelin

We may earn a commission if you purchase through this link, at no extra cost to you.

FDA-Approved Dosing

Tesamorelin has a well-defined dosing protocol established through its FDA approval:

ParameterDetail
Dose2 mg daily
RouteSubcutaneous injection
SiteAbdominal area, rotating injection sites
TimingOnce daily, at the same time each day
AssessmentEvaluate at 26 weeks; discontinue if no improvement in visceral fat

The 2mg daily dose was determined through dose-ranging studies and confirmed in Phase 3 pivotal trials. Lower and higher doses were tested, with 2mg providing the optimal balance of efficacy and safety.

Reconstitution

In the commercial formulation (Egrifta SV), tesamorelin comes as a single-vial lyophilized powder reconstituted with 0.5 mL of provided sterile water for injection. The reconstituted solution should be used immediately.

For research-grade tesamorelin in different vial sizes, use the peptide calculator for reconstitution volumes. Follow the reconstitution guide for step-by-step instructions and the injection guide for subcutaneous technique.

Monitoring Requirements

The FDA labeling recommends monitoring during tesamorelin treatment:

  • IGF-1 levels: Monitor periodically. Discontinue if IGF-1 levels become persistently elevated above the age-adjusted upper limit of normal
  • Blood glucose: Monitor fasting glucose and HbA1c, particularly in patients with diabetes risk factors. Tesamorelin can impair glucose tolerance
  • Visceral fat: Assess by CT or other imaging at 26 weeks. Discontinue if no meaningful reduction
  • Hypersensitivity: Monitor for allergic reactions, particularly during initial administrations

Timing Considerations

Tesamorelin's label specifies once-daily injection without specific timing relative to meals. However, some clinicians recommend:

  • Injecting at a consistent time each day to maintain stable GH stimulation
  • Morning administration to align with the body's natural cortisol and GH rhythms
  • Avoiding injection immediately after high-carbohydrate meals, as elevated blood glucose can blunt GH release

The half-life of tesamorelin is approximately 26 minutes, but the GH release it triggers lasts for several hours.

Frequently Asked Questions

References

  1. Falutz J, et al.. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients. JAMA, 2014.

Researching peptides? We did the hard part.

Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.

Related Guides

PI

Peptides Insider Editorial Team

Our content is reviewed for accuracy and grounded in peer-reviewed research where available. We do not provide medical advice. Always consult a qualified healthcare professional.